|
1.
|
Malfertheiner P, Bazzoli F, Delchier JC,
et al Pylera Study Group: Helicobacter pylori eradication
with a capsule containing bismuth subcitrate potassium,
metronidazole, and tetracycline with omeprazole versus
clarithromycin-based triple therapy: a randomised, open-label,
non-inferiority, phase 3 trial. Lancet. 377:905–913. 2011.
View Article : Google Scholar
|
|
2.
|
Suerbaum S and Michetti P: Helicobacter
pylori infection. N Engl J Med. 347:1175–1186. 2002. View Article : Google Scholar
|
|
3.
|
Malfertheiner P, Chan FK and McColl KE:
Peptic ulcer disease. Lancet. 374:1449–1461. 2009. View Article : Google Scholar
|
|
4.
|
Malfertheiner P, Megraud F, O’Morain C, et
al: Current concepts in the management of Helicobacter
pylori infection: the Maastricht III Consensus Report. Gut.
56:772–781. 2007.PubMed/NCBI
|
|
5.
|
Olbe L, Fändriks L, Hamlet A and
Svennerholm AM: Conceivable mechanisms by which Helicobacter
pylori provokes duodenal ulcer disease. Baillières Best Prac
Res Clin Gastroenterol. 14:1–12. 2000.
|
|
6.
|
Bago J, Majstorovic K, Belosic-Halle Z, et
al: Antimicrobial resistance of H. pylori to the outcome of 10-days
vs. 7-days Moxifloxacin based therapy for the eradication: a
randomized controlled trial. Ann Clin Microbiol Antimicrob.
9:132010. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Gasparetto M, Pescarin M and Guariso G:
Helicobacter pylori Eradication Therapy: Current
Availabilities. ISRN Gastroenterol. 2012:1867342012.PubMed/NCBI
|
|
8.
|
Kaneko E, Hoshihara Y, Sakaki N, et al:
Peptic ulcer recurrence during maintenance therapy with H2-receptor
antagonist following first-line therapy with proton pump inhibitor.
J Gastroenterol. 35:824–831. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Gościniak G: IgG and IgA antibodies in
Helicobacter pylori infections. Zentralbl Bakteriol.
286:494–502. 1997.
|
|
10.
|
Hirschl AM, Rathbone BJ, Wyatt JI, et al:
Comparison of ELISA antigen preparations alone or in combination
for serodiagnosing Helicobacter pylori infections. J Clin
Pathol. 43:511–513. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Rathbone BJ, Wyatt JI, Worsley BW, et al:
Systemic and local antibody responses to gastric Campylobacter
pyloridis in non-ulcer dyspepsia. Gut. 27:642–647. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Gościniak G, Klakockar J,
Przondo-Mordarska A and Mauff G: Helicobacter pylori
antibodies in sera of children suffering from chronic abdominal
pain. Zentralbl Bakteriol. 280:214–220. 1993.
|
|
13.
|
Lascols C, Bryskier A, Soussy CJ and
Tanković J: Effect of pH on the susceptibility of Helicobacter
pylori to the ketolide telithromycin (HMR 3647) and
clarithromycin. J Antimicrob Chemother. 48:738–740. 2001.PubMed/NCBI
|
|
14.
|
Malfertheiner P, Mégraud F, O’Morain C, et
al: Current concepts in the management of Helicobacter
pylori infection--the Maastricht 2-2000 Consensus Report.
Aliment Pharmacol Ther. 16:167–180. 2002.PubMed/NCBI
|
|
15.
|
Corthésy B: Role of secretory
immunoglobulin A and secretory component in the protection of
mucosal surfaces. Future Microbiol. 5:817–829. 2010.PubMed/NCBI
|
|
16.
|
Manojlovic N, Babic D, Filipovic-Ljeshovic
I and Pilcevic D: Anti Helicobacter pylori IgG and IgA
response in patients with gastric cancer and chronic gastritis.
Hepatogastroenterology. 55:807–813. 2008.
|
|
17.
|
Heep M, Kist M, Strobel S, et al:
Secondary resistance among 554 isolates of Helicobacter
pylori after failure of therapy. Eur J Clin Microbiol Infect
Dis. 19:538–541. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Wang WH, Wong BC, Mukhopadhyay AK, et al:
High prevalence of Helicobacter pylori infection with dual
resistance to metronidazole and clarithromycin in Hong Kong.
Aliment Pharmacol Ther. 14:901–910. 2000.
|
|
19.
|
Fujiki S, Iwao Y, Kobayashi M, et al:
Stabilization mechanism of clarithromycin tablets under gastric pH
conditions. Chem Pharm Bull (Tokyo). 59:553–558. 2011. View Article : Google Scholar : PubMed/NCBI
|
